Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697)

被引：26

作者：

Agarwala, S. S.

Lee, S. J.

Flaherty, L. E.

Smylie, M.

Kefford, R. F.

Carson, W. E.

Cohen, G.

Kirkwood, J. M.

机构：

[1] St Lukes Hosp & Hlth Network, Bethlehem, PA USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Wayne State Univ, Detroit, MI USA

[4] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[5] Univ Sydney, Westmead Hosp, Melanoma Inst Australia, Westmead Inst Canc Res, Sydney, NSW 2006, Australia

[6] Ohio State Univ, Columbus, OH 43210 USA

[7] GBMC, Baltimore, MD USA

[8] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

来源：

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.8505

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8505

引用

页数：1